Matthew J Loza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6515347/publications.pdf

Version: 2024-02-01

		172457	1	75258
58	3,221	29		52
papers	citations	h-index		g-index
			_	
58	58	58		4499
30	30	30		4433
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. Journal of Immunology, 2001, 167, 3114-3122.	0.8	315
2	T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. European Respiratory Journal, 2017, 49, 1602135.	6.7	283
3	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. Journal of Allergy and Clinical Immunology, 2017, 139, 1797-1807.	2.9	236
4	Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 560-570.	2.9	166
5	A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 443-455.	5.6	165
6	Final steps of natural killer cell maturation: a model for type 1–type 2 differentiation?. Nature Immunology, 2001, 2, 917-924.	14.5	159
7	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. Journal of Allergy and Clinical Immunology, 2019, 143, 577-590.	2.9	140
8	Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respiratory Research, 2016, 17, 165.	3.6	107
9	Pathway discovery using transcriptomic profiles in adult-onset severe asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1280-1290.	2.9	105
10	The IL-12 Signature: NK Cell Terminal CD56+high Stage and Effector Functions. Journal of Immunology, 2004, 172, 88-96.	0.8	104
11	"T2-high―in severe asthma related to blood eosinophil, exhaled nitric oxide andÂserum periostin. European Respiratory Journal, 2019, 53, 1800938.	6.7	104
12	Expression of type 1 (interferon gamma) and type 2 (interleukin- 13 , interleukin- 5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood, 2002, 99, 1273-1281.	1.4	103
13	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases, 2018, 77, 21-29.	0.9	96
14	Assembly of Inflammation-Related Genes for Pathway-Focused Genetic Analysis. PLoS ONE, 2007, 2, e1035.	2.5	89
15	Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells. Blood, 2006, 107, 2052-2060.	1.4	67
16	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. European Respiratory Journal, 2018, 51, 1702173.	6.7	67
17	Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients. Journal of Allergy and Clinical Immunology, 2017, 140, 710-719.	2.9	57
18	NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. European Journal of Immunology, 2002, 32, 3453-3462.	2.9	54

#	Article	IF	CITATIONS
19	Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell. Molecular Immunology, 2005, 42, 385-395.	2.2	50
20	A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate, 2006, 66, 1556-1564.	2.3	47
21	Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis. Journal of Allergy and Clinical Immunology, 2007, 120, 578-585.	2.9	45
22	Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis. Vaccine Journal, 2011, 18, 931-939.	3.1	44
23	Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study. European Respiratory Journal, 2016, 48, 1307-1319.	6.7	44
24	Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. European Respiratory Journal, 2017, 50, 1602298.	6.7	44
25	Distinction between IL-13+ and IFN- \hat{l}^3 + natural killer cells and regulation of their pool size by IL-4. European Journal of Immunology, 2002, 32, 413-423.	2.9	41
26	Glucocorticoid- and Protein Kinase A–Dependent Transcriptome Regulation in Airway Smooth Muscle. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 24-39.	2.9	39
27	Linear '2–0–1' lymphocyte development: hypotheses on cellular bases for immunity. Trends in Immunology, 2003, 24, 235-241.	6.8	32
28	Contribution of airway eosinophils in airway wall remodeling in asthma: Role of <i><scp>MMP</scp>â€10</i> and <i><scp>MET</scp></i> Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1102-1112.	5.7	32
29	T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus. Cellular Immunology, 2011, 271, 110-117.	3.0	31
30	\hat{l}^2 -Agonist enhances type 2 T-cell survival and accumulation. Journal of Allergy and Clinical Immunology, 2007, 119, 235-244.	2.9	29
31	Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Respiratory Research, 2012, 13, 12.	3.6	26
32	Genetic and epigenetic inactivation of <i>TNFRSF10C</i> in human prostate cancer. Prostate, 2009, 69, 327-335.	2.3	25
33	Peripheral Immature CD2â^'/low T Cell Development from Type 2 to Type 1 Cytokine Production. Journal of Immunology, 2002, 169, 3061-3068.	0.8	22
34	Combined Blockade of TNF-α and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice. Journal of Immunology, 2019, 202, 2017-2026.	0.8	22
35	Type 2″ow asthma phenotypes by integration of sputum transcriptomics and serum proteomics. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 380-383.	5.7	20
36	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open, 2021, 7, e001679.	3.8	19

#	Article	lF	CITATIONS
37	L_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment. PLoS Computational Biology, 2019, 15, e1006951.	3.2	18
38	Safety, tolerability and pharmacokinetics of a human antiâ€interleukinâ€13 monoclonal antibody (<scp>CNTO</scp> 5825) in an ascending singleâ€dose firstâ€inâ€human study. British Journal of Clinical Pharmacology, 2013, 75, 1289-1298.	2.4	16
39	Multiple Color Immunofluorescence for Cytokine Detection at the Single-Cell Level. Molecular Biotechnology, 2003, 23, 245-258.	2.4	15
40	Asthma and gender impact accumulation of T cell subtypes. Respiratory Research, 2010, 11, 103.	3.6	15
41	Differential regulation of NK cell proliferation by type I and type II IFN. International Immunology, 2004, 16, 23-32.	4.0	14
42	Interactive effects of steroids and \hat{l}^2 -agonists on accumulation of type 2 T cells. Journal of Allergy and Clinical Immunology, 2008, 121, 750.e1-755.e3.	2.9	13
43	Responsiveness of Serum Câ€Reactive Protein, Interleukinâ€17A, and Interleukinâ€17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Doubleâ€Blind, Placeboâ€Controlled Trials. Arthritis and Rheumatology, 2019, 71, 1660-1669.	5.6	13
44	Instability of sputum molecular phenotypes in U-BIOPRED severe asthma. European Respiratory Journal, 2021, 57, 2001836.	6.7	13
45	Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. European Respiratory Journal, 2022, 59, 2101733.	6.7	13
46	Clinical and transcriptomic features of persistent exacerbationâ€prone severe asthma in Uâ€BIOPRED cohort. Clinical and Translational Medicine, 2022, 12, e816.	4.0	11
47	Human peripheral CD2â°/lo T cells: an extrathymic population of early differentiated, developing T cells. International Immunology, 2005, 17, 1213-1225.	4.0	9
48	Regulation of T cells in airway disease by beta-agonist. Frontiers in Bioscience - Scholar, 2010, S2, 969-979.	2.1	9
49	Accumulation of type 2 cytokine+ T cells: differentiation-independent proliferation of pre-existing type 2 T cells. European Journal of Immunology, 2003, 33, 939-949.	2.9	8
50	B-Myb Overexpression Results in Activation and Increased Fas/Fas Ligand-Mediated Cytotoxicity of T and NK Cells. Journal of Immunology, 2001, 167, 242-249.	0.8	7
51	Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics. Contemporary Clinical Trials Communications, 2020, 17, 100522.	1.1	6
52	Purification of Peripheral Blood Natural Killer Cells., 2005, 107, 147-162.		5
53	Multiple Color Immunofluorescence for Cytokine Detection at the Single Cell Level. , 2000, 121, 193-209.		3
54	Natural Killer Cells., 2005,, 257-267.		1

#	Article	IF	CITATIONS
55	Exhaled nitric oxide in prednisone-dependent asthma to identify the eosinophilic positive phenotype. Journal of Allergy and Clinical Immunology, 2011, 127, 834.	2.9	1
56	Distinction between IL-13+ and IFN- \hat{l}^3 + natural killer cells and regulation of their pool size by IL-4. , 2002, 32, 413.		1
57	Serological Biomarkers of Progression towards Diagnosis of Rheumatoid Arthritis in Active Component Military Personnel. Arthritis and Rheumatology, 0, , .	5. 6	1
58	SATO103â€LONGITUDINAL PRE-DISEASE TO DISEASE SERUM SAMPLES IDENTIFY BIOMARKERS THAT ARE UPREGULATED PRIOR TO THE DIAGNOSIS OF RHEUMATOID ARTHRITIS., 2019, , .		0